David Foehr Sells 987 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 987 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $18.00, for a total transaction of $17,766.00. Following the sale, the vice president directly owned 38,613 shares of the company’s stock, valued at $695,034. This represents a 2.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Friday, May 22nd, David Foehr sold 862 shares of CeriBell stock. The shares were sold at an average price of $18.80, for a total transaction of $16,205.60.
• On Tuesday, March 3rd, David Foehr sold 4,560 shares of CeriBell stock. The stock was sold at an average price of $17.80, for a total value of $81,168.00.

CeriBell Trading Up 0.2%

NASDAQ:CBLL traded up $0.03 during trading hours on Tuesday, hitting $18.80. The company had a trading volume of 187,155 shares, compared to its average volume of 322,889. CeriBell, Inc. has a 1 year low of $10.85 and a 1 year high of $24.33. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. The company has a 50-day moving average of $19.08 and a 200 day moving average of $19.19. The company has a market cap of $713.27 million, a P/E ratio of -11.53 and a beta of 0.99.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The firm had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. Sell-side analysts expect that CeriBell, Inc. will post -1.69 earnings per share for the current year.

Institutional Investors Weigh In On CeriBell

Large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its holdings in CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after buying an additional 374,179 shares in the last quarter. Rhumbline Advisers boosted its holdings in CeriBell by 109.9% in the second quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after purchasing an additional 17,177 shares during the period. New York State Common Retirement Fund increased its holdings in CeriBell by 148.6% during the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after purchasing an additional 5,200 shares during the period. Quantbot Technologies LP raised its position in CeriBell by 70.3% in the 2nd quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock valued at $290,000 after purchasing an additional 6,401 shares in the last quarter. Finally, Invesco Ltd. acquired a new position in shares of CeriBell during the second quarter worth about $197,000.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on CBLL shares. Canaccord Genuity Group reduced their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings cut shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 12th. Finally, BTIG Research reissued a “buy” rating and issued a $30.00 target price on shares of CeriBell in a research report on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.